CLK1

PF3D7_1445400 (CLK1) is a nuclear LAMMER-family serine/threonine protein kinase of Plasmodium falciparum that is essential for completion of the asexual blood-stage replication cycle (PMID:21312235). It phosphorylates SR/splicing-factor substrates in vitro, including the plasmodial alternative splicing factor PfASF-1 and the Sky1p substrate Npl3p, implicating CLK1 in post-transcriptional mRNA regulation (PMID:21312235). Consistent with this role, CLK1 localizes to the nucleus via nuclear localization signals upstream of its C-terminal catalytic domain (PMID:21312235), and co-immunoprecipitates with proteins predicted to carry nuclease, phosphatase, or helicase activities, indicating assembly into nuclear gene-regulatory complexes (PMID:21312235). Its kinase activity is potently inhibited in vitro by a 3,6-disubstituted imidazo[1,2-b]pyridazine compound (IC50 32 nM), establishing CLK1 as a biochemically tractable drug target (PMID:27721154). Beyond substrate phosphorylation, nuclear localization, and complex membership, no further mechanistic detail (e.g. in vivo substrates, structural basis of catalysis, or the identity of complex partners) has been characterized in the available corpus.

1. 2001 Low

   Establishing the primary structure defined CLK1 as a LAMMER-family kinase with regulatory features (RS/SR dipeptides, NLSs, DKYD repeats) hinting at splicing-related and nuclear function before any activity was measured.

   Evidence Vectorette PCR cloning, genomic restriction analysis, and sequence analysis of the single-copy gene

   PMID:11306117

   Open questions at the time

   • Bioinformatic domain assignment without direct functional assay
   • Sequence homology to Arabidopsis AFC3 does not establish substrate specificity
   • Northern-blot-based sexual-stage expression claim not reconciled with later asexual-stage data
2. 2011 Medium

   Reverse genetics, orthogonal localization, and in vitro kinase assays together established CLK1 as a nucleus-localized, essential kinase acting on splicing factors, converting a sequence prediction into a functional model of post-transcriptional regulation.

   Evidence Reverse genetics for essentiality, IFA/Western/EM for nuclear localization, and in vitro kinase assays on Npl3p and PfASF-1

   PMID:21312235

   Open questions at the time

   • In vitro substrate phosphorylation not confirmed for endogenous substrates in vivo
   • No active-site mutagenesis to prove the phosphorylation depends on CLK1 catalytic activity
   • Essentiality phenotype describes failure to complete the asexual cycle but does not pinpoint the arrested step
3. 2011 Low

   Co-IP/MS asked which partners CLK1 works with, placing it in nuclear complexes containing predicted nuclease, phosphatase, and helicase activities and framing it as part of a gene-regulatory machine.

   Evidence Single co-immunoprecipitation followed by mass spectrometry

   PMID:21312235

   Open questions at the time

   • Single co-IP/MS without reciprocal validation of interactions
   • Partner functions only predicted bioinformatically, not experimentally confirmed
   • Direct versus indirect association within the complex not resolved
4. 2016 Medium

   Enzymatic inhibitor profiling addressed whether CLK1 is druggable, showing potent nanomolar inhibition by an imidazo[1,2-b]pyridazine and validating it as a biochemical target for antimalarial development.

   Evidence In vitro kinase inhibition assay with IC50 determination (compound 20a, 32 nM)

   PMID:27721154

   Open questions at the time

   • No structural or mutagenesis follow-up to define the binding mode
   • In vitro inhibition not linked to on-target killing of parasites in cellulo
   • Selectivity over host or parasite sibling kinases not established

• The in vivo substrate repertoire, the composition and function of the CLK1 nuclear complex, and the mechanistic basis of its essentiality remain unresolved.
• No endogenous phosphoproteomic identification of CLK1 substrates
• Identity and direct-binding status of nuclear complex partners unknown
• No structural model of the catalytic domain or inhibitor-bound state